My interests include the discovery, engineering and in vitro characterization of high potential immunoglobulin fragments of therapeutic interest, and their subsequent advancement into the clinical translational pipeline. My expertise encompasses several selection technologies (e.g. Phage and Ribosome display), protein engineering, and the biophysical and in vitro cell characterization of protein drug candidates in a variety of formats (e.g. IgG, scFv-Fc, CAR, alternative scaffolds etc.)
I worked as a Senior Research Associate in Protein Engineering in Zürich-based Molecular Partners AG pharmaceutical company where I contributed to the discovery of several therapeutic protein drugs (‘DARPins’) now in clinical phases. I joined the LAbCore immunoglobulin discovery platform, under Dr Steven Dunn in the laboratory of Pr George Coukos in 2015.
My research interests include molecular biology, immuno-oncology and cancer therapeutics. My main role is in cell line engineering and to assist in the development and evaluation of lead candidate immunoglobulins and related molecules with high therapeutic potential in a variety of formats (IgG, scFv, CARs, BITEs etc.).
I am a biology graduate from the University of Patras, Greece and I hold a PhD in Biology from the University of Athens. In addition, I have four years of postdoctoral experience in the institutes of Thorax Foundation, Greece, the Karolinska Institute and the Biomedical Research Foundation Academy of Athens (BRFAA). I joined the LAbCore immunoglobulin discovery platform, under Dr Steven Dunn in the laboratory of Pr George Coukos in 2018.
I am involved in the general bio-molecular discovery process, identifying and characterizing novel immunoglobulin candidates through the application of phage display technology and antibody engineering. In this role I contribute to de novo discovery campaigns and humanization programs, running complex assays and establishing several protein analytical characterization tools.
I obtained my Master’s in Biotechnology in 2007 at the University of Milan and I started my career in immuno-oncology research by investigating novel mechanisms involved in the development of acute myeloid Leukemia. I subsequently worked as a research associate from 2011 to 2014 at AXXAM in Milan, contributing to drug compound screening campaigns, before joining the LAbCore immunoglobulin discovery platform under Dr Steven Dunn in the laboratory of Pr George Coukos in 2014.
In my PhD project, I am aiming to develop tools and resources to identify novel, non-TCR, pMHC targeting reagents with improved peptide-dependent selectivity. In concert, I am exploring the development of new in vitro phage display tools that will allow a better assessment of the potential cross-reactivity of any given pMHC-targeting molecule, whether native/orphan TCR, engineered TCR, or alternative binding reagent. With the focus on cancer neo-epitopes, the integration of these approaches may advance the development of personalized cancer therapeutics.
I joined the LAbCore immunoglobulin discovery platform under Dr Steven Dunn in the laboratory of Pr George Coukos as a PhD student in July 2020 after completing my Bachelor’s and Master’s in Biochemistry at Charles University, Prague. During my master’s, I worked within the Laboratory of Structural Biochemistry of Immune Recognition at the Faculty of Science, where I focused on the preparation and characterization of novel bi-specific NK engagers with potential for cancer immunotherapy.
Contributing to the development of a molecular biology platform to help streamline phage display discovery and downstream screening and functional assays. This includes tools that allow convenient antigen expression and capture approaches (eg. via SpyTag/SpyCatcher) and also the routine manipulation and formatting of various immunoglobulin constructs using a modular vector system. Cloning activities typically involve scFvs, Fabs, IgGs, TCRs, T cell engagers, CARs, and pMHC constructs, in phagemid, plasmid, and lentiviral-based vectors.
I joined the Department of oncology in 2013 as a technician in the newly established laboratory of Pr George Coukos, before transferring to help set up a dedicated immunoglobulin discovery and engineering platform, LAbCore, under Dr Steven Dunn. Prior to this, for 25 years I worked as a technical research assistant in the areas of protein engineering and antibody technologies (MerckSerono), molecular biology (Serono), and yeast studies and microbiology (Glaxo). Additionally, I worked for 3 years Quality Control (Biogen). I obtained my « License en Sciences Naturelles » from the University of Lausanne.
My research interests include the discovery and development of antibodies and antibody-like molecules with the therapeutic potential to address unmet clinical needs. Key competencies include the construction of large repertoire libraries, and using display technologies and protein screening and engineering strategies in order to identify and advance promising candidates.
I joined the LAbCore immunoglobulin discovery platform in 2020 under Dr Steven Dunn in the laboratory of Pr George Coukos. Prior to this I worked at Ichnos Sciences in Epalinges as a Senior Research Investigator in the antibody discovery group, looking to identify new bi-specific antibodies for immuno-oncology applications. Previously, I had worked for 5 years in Cambridge, UK, for various biotech companies (F-Star, Ossianix, Bicycle Therapeutics), using phage/yeast display technologies in order to identify new immuno-oncological drugs and neurodegenerative disease therapies. I hold a Master’s degree in Biotechnology Engineering from Polytech Marseille (formerly ESIL, School of Advanced Studies in Engineering).
Human integrated tumor immunology discovery engine (Hi-TIDe)
Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne
Phone +41 21 692 59 51
Fax +41 21 692 59 95
Ch. des Boveresses 155